MGC29506 Activators
MGC29506 activators comprise a diverse array of chemical compounds that each impact intracellular signaling cascades, culminating in the enhanced functional activity of MGC29506. Compounds like Forskolin and IBMX increase cAMP levels, which then activate PKA, a kinase that could phosphorylate and thus potentially activate MGC29506. Similarly, the PKC activator PMA and calcium ionophores such as Ionomycin elevate intracellular PKC activity and calcium levels, respectively. These changes can initiate a cascade of events leading to the activation of MGC29506, assuming that it is a substrate or regulator within these pathways. The anti-oxidant EGCG may inhibit kinases that negatively regulate MGC29506, leading to its functional enhancement, while LY294002 and U0126, by modulating PI3K/AKT/mTOR and MAPK/ERK pathways, respectively, could also shift the balance of cellular signaling in favor of MGC29506 activation.
Further influencing the activity of MGC29506 are inhibitors such as SB203580, a p38 MAPK inhibitor, and Staurosporine, a broad-kinase inhibitor, which may indirectly enhance MGC29506 activity by modulating thekinetic landscape of their respective pathways. Inhibiting p38 with SB203580 might trigger a compensatory mechanism that activates MGC29506, while Staurosporine's broad inhibition of kinases could inadvertently lift suppression on MGC29506 or related pathways. Lipid signaling modulation by Sphingosine-1-phosphate (S1P) could lead to G protein-coupled receptor activation, which in turn may enhance MGC29506 activity if it is incorporated within those signaling routes. Lastly, Genistein's inhibition of tyrosine kinases may reduce competitive substrate phosphorylation, thus freeing up pathways that enhance the activity of MGC29506.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin elevates intracellular cAMP levels, which in turn activates protein kinase A (PKA). PKA activation can lead to phosphorylation of target proteins that may include MGC29506, thereby enhancing its functional activity within its specific signaling pathways. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX acts as a nonspecific inhibitor of phosphodiesterases, leading to increased cAMP levels in cells. This rise in cAMP could indirectly activate MGC29506 through the same PKA-dependent mechanisms as Forskolin. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a diacylglycerol analog which activates protein kinase C (PKC). PKC-mediated signaling can lead to modulation of proteins downstream or in parallel pathways, potentially enhancing the activity of MGC29506. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $94.00 $259.00 | 2 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, activating calcium-dependent protein kinases and phosphatases that could subsequently enhance the activity of MGC29506. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG inhibits certain protein kinases and has been shown to alter signaling pathways. This may lead to a reduction in negative regulation of MGC29506, thus increasing its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that modulates the PI3K/AKT/mTOR pathway, potentially leading to an increased activity of MGC29506 if the protein is functionally downstream of this signaling cascade. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that could change the activity within the p38 MAPK pathway, potentially leading to the activation of MGC29506 if the protein is modulated by this pathway. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor that can lead to selective activation of certain pathways by inhibiting negative regulatory kinases, potentially enhancing MGC29506 activity. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
Sphingosine-1-phosphate (S1P) is a bioactive lipid that acts as a signaling molecule and can activate G protein-coupled receptors to influence various cellular signaling pathways, potentially enhancing the activity of MGC29506. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that may lead to the activation of MGC29506 by reducing the competitive phosphorylation of other substrates, thus favoring pathways that MGC29506 is involved in. | ||||||